全球非酒精性脂肪性肝炎生物标记市场：市场规模、份额、趋势分析（按类型、最终用途和地区）、细分市场预测（2025-2030 年）

非酒精性脂肪性肝炎生物标记市场成长与趋势：

根据 Grand View Research 的最新报告，全球非酒精性脂肪性肝炎生物标记市场规模预计到 2030 年将达到 56.8 亿美元，预测期内的复合年增长率为 23.3%。

由于肥胖和糖尿病等因素导致非酒精性脂肪性肝炎 (NASH) 盛行率不断上升，大大推动了对 NASH 生物标记的需求。非酒精性脂肪性肝炎 (NASH) 诊断数量的不断增加推动了对准确诊断工具的需求。此外，政府和医疗保健部门的倡议提高了人们的认识、早期发现和研究津贴，进一步推动了市场成长。这些努力对于解决日益加重的 NASH 负担和透过生物标记开发改善疾病管理至关重要。

诊断技术的进步和对早期检测的日益关注正在推动 NASH 生物标记市场的成长。影像技术和血液生物标记等创新的非侵入性检测方法可以实现更快、更准确的诊断。早期发现可改善治疗效果，因此对监测病情进展的先进生物标记的需求日益增加。因此，医疗保健系统对早期疗育的日益重视正在推动市场成长，并有助于提供更好的 NASH 管理解决方案。

人们对 NASH 的认识不断提高，预计将推动对有效生物标誌物的需求，从而带来显着的市场成长。提高对疾病的认识有助于更早诊断和更好地管理疾病。该领域的扩大研究和开发将有助于发现新的生物标记并提高诊断的准确性和治疗策略。这些因素预计将推动对 NASH 生物标记的需求并促进市场扩张。

非酒精性脂肪性肝炎生物标记市场：分析概述

• 根据类型，血清生物标记部分将在 2024 年占据市场最大收益占有率，达到 31.2%。
• 预计肝纤维化生物标记部分在预测期内将以最快的复合年增长率增长，因为它在评估肝损伤的严重程度和进展方面发挥关键作用。
• 根据最终用途，製药和 CRO 行业预计将在 2024 年占据最大份额，因为它在药物开发、临床试验和生物标记检验中发挥重要作用。
• 由于人们认识的提高和对早期检测和诊断的需求的增加，诊断实验室部门将成为 2025 年至 2030 年间成长最快的部门。
• 预计到 2024 年，北美将占据最大份额，约为 54%，这得益于其先进的医疗基础设施、对肝病的高度认识以及大量的研究投入。

目录

第一章 分析方法与范围

第二章执行摘要

3. 非酒精性脂肪性肝炎生物标记市场：驱动因素、趋势与范围

• 市场联动展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制分析
• 非酒精性脂肪性肝炎生物标记市场：分析工具
  • 产业分析：波特五力分析
  • PESTEL分析

第四章非酒精性脂肪性肝炎生物标记市场：按类型进行的估计和趋势分析

• 类型细分仪表板
• 非酒精性脂肪性肝炎生物标记市场：按类型进行变异分析
• 全球非酒精性脂肪性肝炎生物标记市场：市场规模和趋势分析（按类型）（2018-2030 年）
• 血清生物标记
• 肝纤维化生物标记
• 细胞凋亡生物标誌物
• 氧化压力生物标誌物
• 其他的

5. 非酒精性脂肪性肝炎生物标记市场：依最终用途的估计和趋势分析

• 最终用途细分仪表板
• 非酒精性脂肪性肝炎生物标记市场：依最终用途进行变异分析
• 全球非酒精性脂肪性肝炎生物标记市场：市场规模和趋势分析（按最终用途划分）（2018-2030 年）
• 製药和CRO行业
• 医院
• 诊断实验室
• 学术研究所

6. 非酒精性脂肪性肝炎生物标记市场：各地区预测及趋势

• 市场仪表板：按地区
• 各地区市场占有率分析（2024 年及 2030 年）
• 非酒精性脂肪性肝炎生物标记市场：关键要点
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 丹麦
  • 瑞典
  • 挪威
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 澳洲
  • 泰国
• 拉丁美洲
  • 巴西
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第七章 竞争态势

• 主要市场参与企业的近期趋势和影响分析
• 公司/竞争对手分类
• 供应商格局
  • Key Company Heat Map Analysis, 2024
• 公司简介
  • GENFIT
  • Prometheus Laboratories
  • Siemens Healthineers AG
  • BioPredictive
  • Quest Diagnostics
  • AstraZeneca
  • Exalenz Bioscience Ltd（meridian bioscience）
  • Labcorp
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 5.68 billion by 2030 and expand at a CAGR of 23.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

• On the basis of type, the serum biomarkers segment led the market with the largest revenue share of 31.2% in 2024, attributed to their ability to provide non-invasive, cost-effective, reliable diagnostic options.
• The hepatic fibrosis biomarkers segment is projected to grow at the fastest CAGR during the forecast period, fueled by their crucial role in assessing the severity and progression of liver damage.
• On the basis of end use, the pharma & CRO industry segment dominated the market with the largest share in 2024, driven by its critical role in drug development, clinical trials, and biomarker validation.
• The diagnostic labs segment is set to be the fastest-growing segment from 2025 to 2030 due to increasing awareness and the rising demand for early detection and diagnosis.
• North America accounted for the largest share of almost 54% in 2024, owing toits advanced healthcare infrastructure, high awareness of liver diseases, and substantial research investments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Scenario

Chapter 3. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
• 4.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
• 4.4. Serum Biomarkers
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Hepatic Fibrosis Biomarkers
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Apoptosis Biomarkers
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. Oxidative Stress Biomarkers
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
• 5.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 5.4. Pharma & CRO Industry
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Hospitals
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Diagnostic Labs
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Academic Research Institutes
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Non-alcoholic Steatohepatitis Biomarkers Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. U.K.
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.1.3. Competitive Scenario
    • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.3.3. Competitive Scenario
    • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.4.3. Competitive Scenario
    • 6.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.5.3. Competitive Scenario
    • 6.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/ Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. GENFIT
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Prometheus Laboratories
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Siemens Healthineers AG
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. BioPredictive
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Quest Diagnostics
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. AstraZeneca
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Exalenz Bioscience Ltd (meridian bioscience)
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Labcorp
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Pfizer Inc.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Bristol-Myers Squibb Company
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 5 Global Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 6 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
• Table 7 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 8 North America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 9 U.S. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 10 U.S Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 11 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 12 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 13 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 14 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 15 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
• Table 16 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 17 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 18 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 19 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 20 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 21 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 22 France Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 23 France Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 24 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 25 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 26 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 27 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 28 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 29 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 30 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 31 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 32 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 33 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 37 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 38 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 39 China Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 40 China Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 41 India Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 42 India Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 43 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 44 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 45 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 46 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 47 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 48 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 49 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
• Table 50 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 51 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 52 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 53 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 54 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 55 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 59 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 60 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 63 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 64 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
• Table 65 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
• Table 66 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Data Triangulation Techniques
• Fig. 3 Primary Research Pattern
• Fig. 4 Primary Interviews
• Fig. 5 Market Research Approaches
• Fig. 6 Value-Chain-Based Sizing & Forecasting
• Fig. 7 QFD Modeling for Market Share Assessment
• Fig. 8 Market Formulation & Validation
• Fig. 9 Non-alcoholic Steatohepatitis Biomarkers Market: Market Outlook
• Fig. 10 Non-alcoholic Steatohepatitis Biomarkers Competitive Insights
• Fig. 11 Parent Market Outlook
• Fig. 12 Related/Ancillary Market Outlook
• Fig. 13 Penetration and Growth Prospect Mapping
• Fig. 14 Industry Value Chain Analysis
• Fig. 15 Non-alcoholic Steatohepatitis Biomarkers Market Driver Impact
• Fig. 16 Non-alcoholic Steatohepatitis Biomarkers Market Restraint Impact
• Fig. 17 Non-alcoholic Steatohepatitis Biomarkers Market Strategic Initiatives Analysis
• Fig. 18 Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
• Fig. 19 Non-alcoholic Steatohepatitis Biomarkers Market: Type Outlook and Key Takeaways
• Fig. 20 Serum Biomarkers Market Estimates and Forecast, 2018 - 2030
• Fig. 21 Hepatic Fibrosis Biomarkers Market Estimates and Forecast, 2018 - 2030
• Fig. 22 Apoptosis Biomarkers Market Estimates and Forecast, 2018 - 2030
• Fig. 23 Oxidative Stress Biomarkers Market Estimates and Forecast, 2018 - 2030
• Fig. 24 Others Market Estimates and Forecast, 2018 - 2030
• Fig. 25 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
• Fig. 26 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Outlook and Key Takeaways
• Fig. 27 Pharma & CRO Industry Market, 2018-2030 (USD Million)
• Fig. 28 Hospitals Market, 2018-2030 (USD Million)
• Fig. 29 Diagnostic Labs Market, 2018-2030 (USD Million)
• Fig. 30 Academic Research Institutes Market, 2018-2030 (USD Million)
• Fig. 31 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Movement Analysis
• Fig. 32 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Outlook and Key Takeaways
• Fig. 33 North America Market Estimates and Forecasts, 2018 - 2030
• Fig. 34 U. S. Market Estimates and Forecasts, 2018 - 2030
• Fig. 35 Canada Market Estimates and Forecasts, 2018 - 2030
• Fig. 36 Mexico Market Estimates and Forecasts, 2018 - 2030
• Fig. 37 Europe Market Estimates and Forecasts, 2018 - 2030
• Fig. 38 U. K. Market Estimates and Forecasts, 2018 - 2030
• Fig. 39 Germany Market Estimates and Forecasts, 2018 - 2030
• Fig. 40 France Market Estimates and Forecasts, 2018 - 2030
• Fig. 41 Italy Market Estimates and Forecasts, 2018 - 2030
• Fig. 42 Spain Market Estimates and Forecasts, 2018 - 2030
• Fig. 43 Denmark Market Estimates and Forecasts, 2018 - 2030
• Fig. 44 Sweden Market Estimates and Forecasts, 2018 - 2030
• Fig. 45 Norway Market Estimates and Forecasts, 2018 - 2030
• Fig. 46 Asia Pacific Market Estimates and Forecasts, 2018 - 2030
• Fig. 47 Japan Market Estimates and Forecasts, 2018 - 2030
• Fig. 48 China Market Estimates and Forecasts, 2018 - 2030
• Fig. 49 India Market Estimates and Forecasts, 2018 - 2030
• Fig. 50 South Korea Market Estimates and Forecasts, 2018 - 2030
• Fig. 51 Australia Market Estimates and Forecasts, 2018 - 2030
• Fig. 52 Thailand Market Estimates and Forecasts, 2018 - 2030
• Fig. 53 Latin America Market Estimates and Forecasts, 2018 - 2030
• Fig. 54 Brazil Market Estimates and Forecasts, 2018 - 2030
• Fig. 55 Argentina Market Estimates and Forecasts, 2018 - 2030
• Fig. 56 Middle East & Africa Market Estimates and Forecasts, 2018 - 2030
• Fig. 57 South Africa Market Estimates and Forecasts, 2018 - 2030
• Fig. 58 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
• Fig. 59 UAE Market Estimates and Forecasts, 2018 - 2030
• Fig. 60 Kuwait Market Estimates and Forecasts, 2018 - 2030